FDA label
What is Entyvio used for?
Entyvio contains vedolizumab. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC); moderately to severely active Crohn's disease (CD).”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Entyvio?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Entyvio, injection, solution
Indications and Usage, quoted from the label by Takeda Pharmaceuticals America, Inc. (BLA761133). Cross-references to other label sections are left out.
ENTYVIO is indicated in adults for the treatment of:
- moderately to severely active ulcerative colitis (UC).
- moderately to severely active Crohn's disease (CD).
Source: DailyMed label, set id 6e94621c-1a95-4af9-98d1-52b9e6f1949c, version 26, effective April 29, 2026. NDC 64764-107, one of 1 listing for this product.
Questions
What is Entyvio used for?
The FDA label says: “ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC); moderately to severely active Crohn's disease (CD).”
What drug class is Entyvio?
FDA lists vedolizumab in the Integrin Receptor Antagonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.